Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buspirone extended release - Cingulate Therapeutics

Next Previous
X
Search
Drug Profile

Buspirone extended release - Cingulate Therapeutics

Alternative Names: Buspirone hydrochloride; CTx-2103

Latest Information Update: 06 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cingulate Therapeutics
  • Class Antidepressants; Anxiolytics; Ketones; Piperazines; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action 5-HT1A serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Anxiety disorders

Most Recent Events

  • 06 Jan 2025 Chemical structure information added.
  • 01 Dec 2023 Cingulate Therapeutics plans to file an IND application with the US FDA for Anxiety disorders in USA, in the first half of 2024
  • 01 Dec 2023 Cingulate Therapeutics receives guidance from the US FDA for the IND application and the design of clinical studies of buspirone in Anxiety disorders (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top